Sinarmas Land to purchase London property for S$161m

It's a 12-storey tower.

In a release, Sinarmas Land Limited announced that it has entered into an agreement for the sale and purchase of the property known as New Brook Buildings, 8-18 Great Queen Street, London, United Kingdom.

This will be through the sale and purchase of (a) the entire issued units of the Unit Trust; and (b) the entire issued share capital of the nominees, for an aggregate cash consideration of £84,046,910.47 (equivalent to approximately S$161,117,927) plus the amount (if any) by which the value of the current assets of the Unit Trust less its liabilities  exceeds £0 (zero), or minus the amount (if any) by which the Completion Statement Value falls short of £0 (zero), upon the terms and subject to the conditions set out in the agreement.

The property is a freehold Grade A office building consisting of a 12-storey tower connected to a 9-storey wing, with a net lettable area of approximately 99,911 square feet.

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare